Fortrea (NASDAQ:FTRE) Price Target Raised to $26.00 at Truist Financial

Posted by George Bondi on Jul 31st, 2026

Fortrea (NASDAQ:FTRE – Free Report) had its target price upped by Truist Financial from $19.00 to $26.00 in a research report report published on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

FTRE has been the topic of several other reports. Citigroup lifted their price objective on Fortrea from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Barclays increased their target price on Fortrea from $18.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Thursday. Wall Street Zen cut Fortrea from a “buy” rating to a “hold” rating in a research note on Tuesday, July 21st. TD Cowen reaffirmed a “buy” rating on shares of Fortrea in a research note on Wednesday, May 6th. Finally, Evercore reaffirmed an “outperform” rating on shares of Fortrea in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Fortrea currently has a consensus rating of “Moderate Buy” and an average target price of $19.75.

Check Out Our Latest Stock Analysis on Fortrea

Fortrea Price Performance

Shares of Fortrea stock opened at $19.08 on Thursday. The business has a 50 day moving average of $16.93 and a 200 day moving average of $13.80. Fortrea has a 52 week low of $5.26 and a 52 week high of $21.39. The company has a market cap of $1.80 billion, a PE ratio of -20.97, a P/E/G ratio of 0.62 and a beta of 2.03. The company has a quick ratio of 0.95, a current ratio of 0.96 and a debt-to-equity ratio of 1.98.

Fortrea (NASDAQ:FTRE – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.05. The business had revenue of $678.20 million for the quarter, compared to analysts’ expectations of $647.57 million. Fortrea had a negative net margin of 3.18% and a positive return on equity of 10.72%. As a group, equities research analysts forecast that Fortrea will post 0.8 earnings per share for the current year.

Institutional Trading of Fortrea

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Larson Financial Group LLC lifted its stake in shares of Fortrea by 136.7% in the fourth quarter. Larson Financial Group LLC now owns 1,856 shares of the company’s stock worth $32,000 after buying an additional 1,072 shares in the last quarter. Osaic Holdings Inc. grew its holdings in shares of Fortrea by 74.3% during the second quarter. Osaic Holdings Inc. now owns 6,844 shares of the company’s stock valued at $38,000 after buying an additional 2,918 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Fortrea by 137.0% during the second quarter. Tower Research Capital LLC TRC now owns 8,713 shares of the company’s stock valued at $43,000 after acquiring an additional 5,036 shares in the last quarter. Toronto Dominion Bank purchased a new position in Fortrea in the 4th quarter worth approximately $51,000. Finally, EverSource Wealth Advisors LLC raised its holdings in Fortrea by 662.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 11,963 shares of the company’s stock worth $59,000 after acquiring an additional 10,395 shares during the last quarter.

Fortrea News Roundup

Here are the key news stories impacting Fortrea this week:

Positive Sentiment: Fortrea reported second-quarter adjusted earnings of $0.23 per share, exceeding the $0.18 analyst consensus, while revenue of $678.2 million topped expectations of $647.6 million. Earnings also increased from $0.19 per share a year earlier. Fortrea Q2 Earnings Beat
Positive Sentiment: The company raised or increased its full-year outlook, forecasting 2026 revenue of approximately $2.62 billion to $2.69 billion. Management highlighted four consecutive quarters of improved commercial, operational and financial execution, supporting the bullish case. Fortrea Reports Second Quarter 2026 Results
Positive Sentiment: Truist Financial raised its price target on Fortrea from $19 to $26 and upgraded the stock to “Buy,” implying substantial potential upside from recent trading levels. The change reflects increased confidence following the earnings results and guidance. Truist Raises Fortrea Price Target
Neutral Sentiment: Fortrea’s positive quarterly performance was accompanied by a negative net margin, indicating that profitability remains uneven despite the adjusted earnings beat. Analysts currently expect approximately $0.80 in earnings per share for the full fiscal year. Fortrea Earnings Report
Negative Sentiment: The board appointed director David Smith as interim chief financial officer amid an ongoing legal dispute involving former CFO Michael Madlock and a related covenant proceeding. The management transition and legal uncertainty could weigh on investor confidence and partially offset the strong operating results. Fortrea Names Interim CFO

Fortrea Company Profile

(Get Free Report)

Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.